ALX ONCOLOGY HOLDINGS INC (ALXO)
Health Care · Immuno-oncology / checkpoint inhibitors · NASDAQ
An early-stage immuno-oncology biotech advancing a next-generation CD47 blocker designed to restore macrophage tumor-killing when combined with targeted cancer therapies.
What ALX ONCOLOGY HOLDINGS INC does
ALX Oncology is a clinical-stage biotechnology company developing novel immuno-oncology therapies to treat cancer. The company's lead candidate is evorpacept (ALX 148), a next-generation CD47 blocker designed to enhance macrophage-mediated tumor cell killing when combined with other anti-cancer agents. Its second pipeline candidate is ALX2004, an EGFR-targeted antibody-drug conjugate (ADC) that entered Phase 1 trials in 2025. The company has no approved products or product revenue to date.
Themes: ["CD47 checkpoint inhibitors / macrophage activation","Immuno-oncology","Cancer immunotherapy combinations","HER2-positive breast cancer","Gastric/esophageal junction cancer","EGFR-targeted therapies"]
Fundamentals
- Price$2.06 as of 2026-07-09 close
- Market cap$277M as of 2026-07-10
- 1-year return+408.0% as of 2026-07-09 close
- Net margin-753.5% as of 2026-07-10
- Gross margin+9.0% as of 2026-07-10
- ROE-124.1% as of 2026-07-10
- Debt / equity0.07 as of 2026-07-10
- Beta0.38 as of 2026-07-10
Key risks (from latest filing)
["Company has never generated product revenue and expects significant net losses for the foreseeable future; substantial additional capital will be required to continue operations","Lead candidate evorpacept has not completed a pivotal trial; clinical development is expensive, lengthy, and unpredictable with no guarantee of regulatory approval or commercial success","High dependence on key personnel and third-party manufacturers for clinical supplies; relies on patent protection in a competitive immuno-oncology landscape"]
Competitors & peers
- Trillium Therapeutics (TRIL) - CD47 blockers and myeloid immunotherapy
- Forty Seven Inc. (merged with Gilead) - CD47-targeted therapeutics
- Incyte Corporation (INCY) - immuno-oncology agents
- Jounce Therapeutics - checkpoint immunotherapy
- Calithera Biosciences - immuno-oncology metabolic targets
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.